The acridone alkaloid acronycine (1), which was first isolated from Acronychia baueri SCHOTT (Rutaceae) in 1948, was later found to be a potent anticancer agent. [1] [2] [3] [4] [5] It is of interest because of its activity against a broad spectrum of solid tumors, including numerous sarcomas, myelomas, carcinomas, and melanomas.
The replacement of the dimethylpyran D ring of acronycine by a pyridine unit, present in numerous tetracyclic antitumor drugs including the linear ellipticines [10] [11] [12] and olivacines, [13] [14] [15] and their angular 7H-and 11H-pyridocarbazoles counterparts, [16] [17] [18] [19] appeared to us an attractive way to look for new anticancer candidates. In addition, this approach was consistent with the antitumor activities of several recently described benzophenanthrolinones related to amsacrine. 20) This paper deals with the synthesis and cytotoxic properties of 12H-benzo[b] [1, 7] and [1, 10] phenanthrolinones related to acronycine, and also to 6-demethoxyacronycine (2) and 11-aminoacronycine (3), which were shown to exhibit cytotoxic activities within the same range of magnitude as acronycine itself. 9, 21) Chemistry The key-step of our approach was an Ullmann condensation 22) of either 2-bromobenzoic acid (4) or 2-chloro-3-nitrobenzoic acid (5) with suitable aminoquinolines 6-8, to afford the carboxylic phenylquinolylamines 9-13. Cyclization to the corresponding 12H-benzo[b] [1, 7] phenanthrolin-7-ones 14 and 15, and 12H-benzo[b] [1, 10] phenanthrolin-7-ones 16-18 was obtained by use of trifluoroacetic anhydride 21, 23) or concentrated sulfuric acid. 20, 24) Methylation at N-12 using methyl iodide under classical or phase-transfer catalyzed conditions 21, 23) could only be ensured in the cases of compounds 14, 16, and 17, which bear no bulky nitro substitutent at C-11. This reaction gave access to 6-demethoxyacronycine analogues 12-methyl-12H-benzo[b] [1, 7] phenanthrolin-7-one (19) and 12-methyl-12H-benzo[b] [1, 10] phenanthrolin-7-one (20) , and to acronycine analogue 6-methoxy-12-methyl-12H-benzo[b] [1, 10] phenanthrolin-7-one (21) . Reduction of the nitro group of 18 by catalytic hydrogenation gave 11-amino-12H-benzo[b] [1, 10] phenanthrolin-7-one (22) . In contrast, all attempts towards the reduction of the nitro group of 15 failed, most probably due to the almost complete insolubility of this compound in usual organic solvents.
Pharmacology The study of the biological properties of the new benzophenanthrolin-7-one derivatives was carried out in vitro on L1210 murine leukemia cell line. The results (IC 50 ) are reported in Table 1 
Results and Discussion
Considering the structure-activity relationships, it appears that in the 12H-benzo[b] [1, 10] phenanthrolin-7-one series, only compounds 18 and 22, bearing a nitrogen substitutent at position 11, exhibited significant cytotoxic activity. Unsubstituted compounds 16, 17, 20, and 21 were devoid of significant activity. Surprisingly, it should be noted that compound 16, previously prepared as an intermediate in the course of the preparation of amsacrine analogues, was reported to be highly cytotoxic. 20) Interestingly, 12H-benzo[b] [1, 7] phenanthrolin-7-ones 14 and 19, which include a pyridine nitrogen in the same 4-position as the pyran oxygen of acronycine exhibited cytotoxic activities within the same range of magnitude as acronycine itself. The position of the heteroatom in the heterocyclic D ring fused onto the A-B-C acridone tricyclic system therefore appears to have a dramatic influence on the cytotoxic activity.
Experimental
Chemistry Mass spectra were recorded with a Nermag R-10-10C spectrometer using electron impact (MS) and/or desorption chemical ionization (DCI-MS; reagent gas: NH 3 ) techniques. UV spectra (l max in nm) were determined in spectroscopic grade MeOH on a Beckman Model 34 spectrophotometer. IR spectra (n max in cm Ϫ1 ) were obtained in potassium bromide pellets on a Perkin-Elmer 257 instrument.
) and 13 C-NMR spectra were recorded at 300 MHz and 75 MHz, respectively, using a Bruker AC-300 spectrometer. Column chromatography was conducted using flash silica gel 60 Merck (40-63 mm) with an overpressure of 300 mbars.
N-(5-Quinolyl)anthranilic Acid (9): A mixture containing 5-aminoquinoline (6) (216 mg, 1.5 mmol), 2-bromobenzoic acid (4) (301.5 mg, 1.5 mmol), potassium acetate (438 mg, 4.47 mmol), copper(II) acetate monohydrate (12 mg, 0.06 mmol), triethylamine (0.25 ml, 1.77 mmol), and 2-propanol (8 ml) was stirred and heated under reflux for 24 h. After cooling and evaporating the solvent, the residue was treated with 1 N HCl (30 ml) and extracted with CH 2 Cl 2 (3ϫ25 ml). The organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered, and evaporated under reduced pressure. Column chromatography on silica gel (CH 2 Cl 2 /MeOH : 80/20) followed by crystallization from methanol gave 9 (213 mg, 53%) as yellow crystals (5) (14): A solution of 9 (213 mg, 0.86 mmol) in concentrated sulfuric acid (5 ml) was heated at 100°C for 5 h. The cooled solution was poured into ice-water and basified with 30% aqueous NaOH. The solution was extracted with 2-butanone (3ϫ25 ml). The organic layers were dried over anhydrous Na 2 SO 4 , filtered, and evaporated under reduced pressure. Recrystallization from ethanol gave 14 (143 mg, 67%) as a yellow crystalline product, mp: 293°C. IR (KBr) cm
Ϫ1
: 3100-3000, 1620. UV l max (MeOH) nm (log e): 252 (4.02), 280 (3.75), 303 (3.25), 348 (3.24 4 (s, C-12b), 121.1 (d, C-5), 121.9 (d, C-2), 125.6  (d, C-9), 125.7 (s, C-6a), 126.5 (d, C-6), 129.2 (d, C-8), 130.7 (s, C-7a),  131.4 (d, C-1), 136.4 (d, C-10), 141.5 (s, C-12a), 143.9 (s, C-11a), 146.1 (s,  C-11), 151.4 (s, C-4a), 153.0 (d, C-3), 174.1 (s, C-7 (17): A solution of 12 (50 mg, 0.17 mmol) and trifluoroacetic anhydride (1 ml, 7.14 mmol) in anhydrous CH 2 Cl 2 (10 ml) was stirred at room temperature for 3 d. After evaporation of the solvent, the residue was washed with aqueous NaHCO 3 (5%). The aqueous layer was further extracted with CH 2 Cl 2 (2ϫ10 ml 
